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Abstract: Colorectal cancer (CRC) is a malignant tumor arising from a human inner colon lining that may spread to other organs such
as the liver and lungs. Per ARNT Sim domain containing 1 (PASD1) is a cancer-testis antigen expressed in cancers including CRC but
not in normal tissues except for normal testes. This study aims to study PASD1 protein as a potential target for CRC immunotherapy.
A total of 90 CRC and polyps tissue samples were investigated for PASD1 RNA and protein expression using a real-time polymerase
chain reaction and immunohistochemical staining, respectively. Matched patients’ peripheral blood mononuclear cells were pulsed
with PASD1 peptides and measured for immunogenicity, cell cytotoxicity, and cytokine assays. The clinical data were collected and
analyzed accordingly. Our results show that PASD1_v2 mRNA expression was highly expressed in CRC (46.0%) and polyps samples
(33.3%). Both PASD1-1 and PASD1-2 proteins were expressed in 31.7% of CRC and 29.4% of polyps samples. Protein expression was
weak to moderate positive in the cytoplasm and/or nucleus of the tissues. Immune responses towards CD4-specific PASD1 peptides
were detected in 21.7% of CRC and 23.5% of polyps patients. The most immunogenic peptide was PASD1 (1) in CRC while PASD1
(3) in polyps. Cytotoxicity effects were detected up to 57.20% observed in CRC samples while IL-17A and IL-6 cytokines were highly
expressed. The demographic data suggest that Chinese female patients more than 60 years old, diagnosed with late-stage rectosigmoid
tumors may benefit from the PASD1 peptide immunotherapy approach. This is the first report describing CD4-positive T-helper
response to the PASD1 positive CRC patients and its cytotoxicity.
Key words: Colorectal cancer, polyps, immunotherapy, cancer testis antigen, PASD1, CD4 T cell response

1. Introduction
Colorectal cancer (CRC) is a malignant tumor arising
from a human inner colon lining that may spread to
other organs such as the liver and lungs. It is the third
most common cancer worldwide after lung and breast
cancer with 1,931,590 total new cases recorded in 2020
and a mortality of 935,173 total cases (Bray et al., 2018;
Azizah et al., 2019). Current standard treatments for CRC
include surgery, chemotherapy and radiation therapy.
However, 30%–40% of CRC patients who underwent these
treatments experience tumor recurrence within 5 years
of diagnosis. Due to the unspecificity of chemotherapy
and radiotherapy treatments, several mild to severe side
effects in patients such as massive loss of hair, persistent
vomiting, frequent diarrhea and prolonged fatigue were
observed (Schirrmacher, 2019). More specific and welltolerated treatment alternatives are needed in improving
the quality of cancer treatments. One of the options is
targeted immunotherapy. Immunotherapy is a biological

treatment that can naturally stimulate patients’ immune
systems to specifically target and eradicate cancer cells
with lesser side effects (Johdi and Sukor, 2020).
Cancer-testis antigen (CTA) is one of the attractive
and widely studied immunotherapeutic targets due to its
unique expression in various types of cancer cells but is
absent in normal cells except testis tissue (Caballero and
Chen, 2009). One of the CTAs is Per ARNT SIM domain
containing repressor 1 (PASD1). PASD1 (other names:
CT63, CT64, OXTES1) is a novel protein-coding gene
that encodes transcription factor proteins with a PAS
domain, putative leucine zipper and nuclear localization
signal domains within the protein (Liggins et al., 2004).
The PASD1 is located at Xq28 with genomic coordinates
of GRCh38.p12 (151563184-151676739) in the human
chromosome (Caballero and Chen, 2009). The PASD1
function as a biological clock suppressor which regulates
the daily circadian rhythms of cells in humans (Michael
et al., 2015). PASD1 genomic structure consists of two
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transcript variants of PASD1_v1 and PASD1_v2 due to
the alternative splicing (Liggins et al., 2004). The longer
PASD1_v1 transcript consists of 16 exons and a retained
intron located between exons 14 and 15. The presence
of stop codon (TGA) in the retained intron produced
a shorter translated PASD1-1 protein of 639 amino
acid (aa) from this PASD1_v1 transcript. The second
transcript PASD1_v2 translates a 773 aa PASD1-2 protein
with a unique C terminus region. Both of the PASD1
proteins consist of two overlapping PAS domains at the
N terminal region of 32-94 aa and 41-137 aa (Liggins et
al., 2004). PASD1 protein expression in normal testis
tissues was detected in the nucleus and cytoplasm of
primary spermatogonia at testicular tubules near the
basal membrane which are restricted within the earliest
phase of spermatogenesis (Liggins et al., 2004; Cooper
et al., 2006). Its restricted expression patterns within
the human gonads and various cancer cells make it one
of the attractive immunotherapeutic targets. This study
aims to validate PASD1 expression as a potential target
for colorectal cancer immunotherapy by investigating
its expression, immunogenicity of PASD1 peptide in
inducing CD4 T cell immune response, cytotoxicity and
cytokine expression. The results obtained were correlated
with patients’ demographics. The study used a peptidebased cancer vaccine immunotherapy strategy. This type
of approach is easy to synthesize, economical and more
effective compared to other available options.
2. Methods
2.1. Ethical clearance
Ethical approval and written consent were applied
according to the standard procedures of The Universiti
Kebangsaan Malaysia Research Ethics Committee. All
blood and tissue samples used in this study were collected
under the rules and regulations stated. Reference number:
UKM PPI/111/8/JEP-2016-063.
2.2. Samples selection
A total of 90 participants who came to the Endoscopy
Service Centre, Department of Surgery, UKM Medical
Centre from April 2018 to October 2019 and were subjected
to perform full colonoscopy procedures were randomly
approached and recruited in this study. Patients were
assessed and consent was obtained from all participants
before sample collection. There were 60 CRC patients,
17 colorectal polyps patients and 13 healthy controls
participants. All samples were verified by the endoscopy
specialist and histological pathologist.
2.3. Peripheral blood mononuclear cell (PBMC)
PBMCs are specialized immune cells that work together
to protect our body from harmful pathogens. They are
developed in the bone marrow from hematopoietic stem
cells (HSCs). The three main cell categories present in
PBMC composition include lymphocytes, monocytes and
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dendritic cells. PBMCs are collected by isolation from
whole blood samples. In this study, 10 mL of fresh blood
were collected from each patient in BD Vacutainer heparin
tubes (Beckton Dickinson, USA). Samples were kept at 4
°C before further PBMC isolation. Samples were processed
within 24 h postcollection. PBMCs were isolated with
Ficoll Paque PLUS density gradient media (GE Healthcare,
USA) according to the manufacturer’s protocol. Cells
were cryopreserved in 10% of dimethyl sulfoxide solution
(DMSO) in a liquid nitrogen tank (–196 °C) until use.
2.4. Cell lines and the cell culture
The SW480 and HCT116 CRC cell lines were purchased
from the American Type Culture Collection (ATCC,
USA). The cell lines were grown in Gibco Roswell Park
Memorial Institute 1640 (RPMI-1640) culture media
(Life Technologies, USA) supplemented with 10%
heat-inactivated Gibco fetal bovine serum (FBS) (Life
Technologies, USA) at 37 ºC with 5% carbon dioxide (CO2)
concentration. The adherent cell lines were detached using
Gibco 0.05% trypsin-EDTA (Life Technologies, USA)
dissociation agent, washed with 1 X PBS and centrifuged
for 5 min at 100 X g. The supernatant was removed after
centrifugation and the pellet was resuspended in 1 mL of
media before cells counting.
2.5. Real-time quantitative reverse transcription PCR
(qRT-PCR) analysis
Total RNA was extracted from formalin-fixed paraffinembedded (FFPE) sections using RNeasy FFPE Kit
(QIAGEN, Germany) as per the manufacturer’s instruction.
The thickness for each FFPE section was up to 20 µm per
section. RNA extraction from cell lines was performed by
using the RNeasy Mini Kit (QIAGEN, Germany) as per
the manufacturer’s protocol. The extracted nucleic acid
(RNA) was quantified for concentration and purity using
a NanoDrop ND-2000C spectrophotometer (Thermo
Scientific, USA). Samples with RNA concentrations of
more than 10 ng/µL and purity A260/A280 within 1.70 to
2.10 were chosen for qRT-PCR analysis.
PASD1 has 2 different transcripts; PASD1_v1 and
PASD1_v2. The qRT-PCR was performed at three different
target sites. Primer A amplified the common region
presented on both PASD1_v1 and PASD1_v2 transcripts.
Primer A (F): 5’-TAC AGG AGC GGA AGA AGT GG3’; Primer A (R): 5’-ACA GGA ACA ATG GGT TGG
G-3’. Primer B amplified the end region of the PASD1_v1
transcript. Primer B (F): 5’- GCC CAC AAA CCT TGA
AAT CAC-3’; Primer B (R) 5’- TCA CAC TCA CTT CCC
TCT TAC-3’. The unique region on the longer PASD1_v2
transcript was amplified by Primer C. Primer C (F): 5’AGC AGA CCA GAT TGA TGC C-3’; Primer C (R): 5’CTA CCC ACT AAA CCC TAC CC-3’. Housekeeping
gene control was GAPDH. GAPDH (F): 5’- CTG ACT
TCA ACA GAG ACA CC-3’; GAPDH (R): 5’-TAG CCA
AAT TCG TTG TCA TAC C-3’. All primers were designed
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using Primer-BLAST. The primers had 50%– 60% GC
content, and 19 to 22 base pairs with 58 to 61 °C melting
points.
The qRT-PCR was performed by using Power SYBR
Green RNA-to-CT 1-Step Kit (Applied Biosystems, USA).
The total volume for each reaction is 20 µL. The reaction was
performed using the standard thermal cycling conditions
as recommended by the manufacturer. Triplicates samples
were run in the Applied Biosystems 7500 Fast Real-time
PCR System machine (Applied Biosystems, USA) and the
Ct value was quantified.
2.6. Staining antibodies
Immunohistochemistry (IHC) was performed using the
in-house PASD1a and PASD1b monoclonal antibodies
(a kind gift from Dr. Kamel Ait-Tahar and his team at
the Nuffield Division of Clinical Laboratory Science,
University of Oxford). PASD1a (clone 2ALCC136) binds
to the epitopes of PASD1-1 and PASD1-2 proteins (195474 aa) within the common region of the N terminus on
both transcripts and its localization is in the nucleus and
cytoplasm of the cells. On the other hand, PASD1b binds
to the unique C terminus region that is only present on
PASD1-2 protein (540-773 aa) and its localization is within
the cell nucleus (Cooper et al., 2006). Normal human testis
and tonsil tissues were used as the positive and negative
biological controls respectively.
2.7. The formalin-fixed paraffin-embedded (FFPE) tissue
block
FFPE blocks from CRC and polyps patients were obtained
from the Department of Pathology, UKMMC and validated
by the pathologist. Only blocks with more than 80% tumor
tissues were selected for IHC staining. The blocks were
sectioned at 5 µm using Leica RM2245 semiautomated
rotary microtome (Leica Biosystems, Germany) and
processed using a standard sectioning protocol.
2.8. Immunohistochemical staining
IHC staining was performed using EnVision FLEX
Mini Kit, High pH, Dako Autostainer/Autostainer Plus
(Dako, Denmark) as per the manufacturer’s instructions.
Tissue sections were incubated with primary antibodies
of PASD1-1 (clone 2ALCC136) and PASD1-2 (clone
2ALCC128) at final concentration of 10 µg/mL for 20 min.
Anti-PASD1 antibodies were treated with horseradish
peroxidase immunoglobulins (HRP) secondary antibody
and detected with 3, 3’-diaminobenzidine (DAB) substrate.
2.9. CD4 PASD1 peptides
All PASD1 peptides were generated using TEPITOPE and
SYFPEITHI prediction algorithm software as described
before (Ait-Tahar et al., 2009; Ait-Tahar et al., 2011). The
peptides were synthesized through standard chemistry
on a multiple peptide synthesizer and were more than
90% pure (a kind gift from Dr. Kamel Ait-Tahar and his
team at Nuffield Division of Clinical Laboratory Science,

University of Oxford). The peptides are listed in Table 1.
Lyophilized peptides were diluted in DMSO and stored at
–20 °C until further usage.
2.10. ELISpot assay
ELISpot assay was performed using the Human Interferongamma (IFN-Ɣ) ELISpotBasic HRP Kit (Mabtech, Sweden)
according to the manufacturer’s instruction. The PBMCs
were pulsed with different peptides [PHA, irCD4, PASD1
(1), PASD1 (2) and PASD1 (3)] at a concentration of
10 µM. After 7 days, PBMC was restimulated with the
respective 10 µM peptides and the cell suspension was
transferred into the antihuman IFN-ɣ coated PVDF
plate. Signals were detected with biotinylated 7-B6-1
detection antibody (Mabtech, Sweden) and streptavidinhorseradish peroxidase (HRP) (Mabtech, Sweden) as
per the manufacturer’s recommendation. The number
of spots formation was quantitated using ImmunoSpot
S6 Universal Elispot/Flourospot Analyser (Cellular
Technology Limited, USA). Each spot represents a positive
IFN-ɣ response towards the peptides.
2.11. T cell expansion
CRC or polyps samples with high IFN-ɣ response towards
PASD1 peptide were selected for further T cell expansion
to generate a T cell line. Cells were cultured in Gibco CTS
OpTmizer T-cell Expansion SFM media (Life Technologies,
USA) and incubated at 37 ºC in 5% CO2. After 72 h, an
equal volume of CTS OpTmizer T-cell Expansion SFM
containing 50 IU/mL of human recombinant interleukin
of IL-2 was added to each well of the 96-well plates. Cell
media was replaced with a fresh medium every 3 days and
cells were restimulated with PASD1 peptide weekly for up
to 5 weeks.
2.12. Cytotoxicity assay
SW480 (PASD1-positive) and HCT116 (PASD1-negative)
target cell lines were cultured as described before and
stained with 0.1 µM BD Pharmingen Calcein AM (BD
Bioscience, USA) for 30 min at 37 °C and protected from
light. The generated patients’ T cell lines were added to the
stained target cells with an effector: target ratio of 10:1,
20:1 and 40:1. Cells were cocultured for 18 h at 37 °C in 5%
CO2. Next, the cocultured cells were labelled with PerCPCy 5.5 mouse antihuman CD3 (BD Bioscience, USA),
5 uL of APC Annexin V (Annexin V) (BD Bioscience,
USA) and Propidium Iodide (PI) staining solution (BD
Bioscience, USA) as per manufacturer’s protocol.
Table 1. List of peptides used in ELISpot assay.
Peptides
CD4 PASD1 (1)
CD4 PASD1 (2)
CD4 PASD1 (3)
CD4 irCD4

Epitopes
(aa)
38–47
167–175
63–71
n/a

Sequence
EVEQYGPQENVHMFVDSTYC
QQQLVQQEQHLKEQQRQLRE
PQDYIRLWQELSDSLGPVVQV
DESFRKYTAFTIPSMNNETP
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2.13. Cytokine profiling
Cytokine profiling was performed using the BD Cytometric
bead array (CBA) human Th1/Th2/Th17 cytokine kit (BD
Bioscience, USA) manufacturer’s instruction. The list of
cytokines detected were interleukin-2 (IL-2), interleukin-4
(IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor
necrosis factor (TNF), interferon-gamma (IFN-ɣ) and
interleukin-17A (IL-17A). Cytokine expression was
quantified with BD FACSVerse flow cytometer (BD
Bioscience, USA). Results were analyzed using FCAP
Array v3.0 software (BD Bioscience, USA).
2.14. Statistical and correlation analysis
The qPCR, ELISpot, apoptosis and cytokine assays results
were analyzed using the Student’s t-test. A statistics of
p-value that measures the probability of obtaining the
observed results, assuming that the null hypothesis is
true used for analysis. The lower the p-value, the greater
the statistical significance of the observed difference. The
p-values < 0.05 were considered significant. Correlation
analysis performed on the patients’ demographic data with
PASD1 expression and CD4 T cell response data was based
on a prospective frequency basis.
3. Results
3.1. Patients demographic data
A total of 90 samples from 3 different groups of patients;
colorectal cancer (CRC) (n = 60), polyps (n = 17)
and normal controls (n = 13) were used in this study
(Supplementary S1). The median age of the CRC, polyps
and normal controls was around 66 years old. Higher male
respondents with an age >60 years old were observed.
Approximately 46.7% of CRC samples were from Malay
and Chinese patients while 58.8% of polyps samples and
53.8% of the normal control samples were Chinese.
Most of the CRC patients (83.3%) had a tumor at the
left side (distal) part of the colon which includes anal,
rectum, rectosigmoid, sigmoid, descending colon and
splenic flexure compared to the right side (proximal).
About 41.7% of these patients were diagnosed at stage III,
indicating cancer has invaded from muscularis propria
into pericolorectal tissue. Out of 61.7% who presented
with nodal metastasis CRC, only 20.0% of patients were
diagnosed with distant metastasis. Adenocarcinoma which
consists of mucinous and synchronous adenocarcinoma
was the commonest type of CRC in this study (98.3%).
Similar to the CRC samples, the polyps were also located at
the left-sided colon (64.7%) with the majority being from
hyperplastic polyps.
3.2. PASD1 mRNA expression
3.2.1. PASD1 mRNA expression in CRC cell lines
PASD1 mRNA was highly expressed in the SW480 CRC
cell line while no PASD1 mRNA was detected in the
HCT116 CRC cell line (Figure 1a). The common region of
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PASD1_v1 and PASD1_v2 mRNA in SW480 cells showed
the highest expression of around 78,000-fold change. Of
these two transcripts, PASD1_v2 expression was higher.
The SW480 cell line was selected as a PASD1 positive cell
line while HCT116 was used as a negative control cell line
throughout the experiment.
3.2.2. PASD1 mRNA expression in clinical samples
A total of 50 out of 60 CRC and 6 out of 17 polyps FFPE
blocks sections were available for qRT-PCR analysis.
These FFPE blocks matched with the ones used for
immunohistochemistry analysis (subsection 3.3). In other
words, 10 CRC and 11 FFPE blocks were not sufficient for
qRT-PCR analysis.
In CRC samples, a total of 14 out of 50 patients
expressed both the PASD1_v1 and PASD1_v2 transcripts
(Table 2). Among the CRC samples, PASD1_v2 was also
frequently expressed (46%) compared to PASD1_v1 (10%).
The expression level of both PASD1_v1 and PASD1_v2
was the highest with 2-fold relative expression compared
to the PASD1_v1 only and PASD1_v2 only (Figure 1b).
The relative PASD1 expression for PASD1_v2 was also
higher compared to the PASD1_v1 transcript by around
1-fold difference. In polyps samples, approximately 33%
(2 out of 6) were PASD1_v1 and PASD1_v2 transcripts
positive (Table 2). The same patients were also presented
with PASD1_v1 only or PASD1_v2 only. Contrary to the
SW480 cell line and CRC sample, PASD1_v1 was expressed
0.5-fold higher than PASD1_v2 in polyps patients (Figure
1c). Overall, PASD1 mRNA expression was higher in the
polyps group compared to the CRC with 1-fold difference.
3.3. PASD1 protein expression
PASD1-1 and PASD1-2 protein staining was carried out
using PASD1a and PASD1b antibodies, respectively.
Positive staining with the PASD1a antibody showed strong
brown staining in the nucleus and cytoplasm of the tissue
while staining with the PASD1b antibody showed strong
staining in the nucleus with no staining in the cytoplasm
(Figure 2).
3.3.1. PASD1 protein expression in CRC
A total of 60 CRC and 17 polyps FFPE blocks sections were
analyzed for immunohistochemistry. CRC tissues showed
moderate staining with both the PASD1a and PASD1b
antibodies. For the PASD1a antibody, staining was mostly
in the nucleus and cytoplasm of the lamina propria and
muscularis mucosa area of the colon tissue while staining
with PASD1b antibody was in the nucleus of the lamina
propria and muscularis mucosa (Figures 2e and 2f).
PASD1-1 and PASD1-2 protein were expressed at varying
degrees and the frequency of this staining is summarized
in Table 3. About 21.7% showed weak positive and 10.0%
with moderate positive using PASD1a antibody and 3.3%
were weakly stained with PASD1b antibody. The PASD1
positive CRC samples were mostly from patients aged
≥ 60 years old (63%) and female (63%) (Supplementary
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Table 2. Frequency of positive PASD1 mRNA detection in CRC
and polyps samples.

CRC (n = 50)

PASD1_v1 and
PASD1_v1 PASD1_v2
PASD1_v2 (n, %) only (n, %) only (n, %)
14 (28.0%)
5 (10.0%)
23 (46.0%)

Polyps (n = 6)

2 (33.3%)

PASD1 primer

Figure 1. PASD1 mRNA expression in (A) SW480 and HCT116,
(B) CRC and (C) polyps samples. Student t-test with * p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001 and p ≤ 0.0001. Error bar indicates mean
with SEM.

S2). Chinese patients were the highest frequency (58%)
compared to other races. About 84.2% of CRC patients
had their tumor in the distal colon and all of the patients
performed surgical resection to remove cancer.
3.3.2 PASD1 protein expression in polyps
The polyps showed weak staining with the PASD1a
antibody (Figure 2g). Most of the positive stained polyps
samples were weakly positive (23.5%) while 5.9% were
stained with moderate positive (Table 3). No PASD1-2
protein was detected in polyps samples using the PASD1b
antibody (Figure 2h). In both CRC and polyps tissues,
PASD1-1 and PASD1-2 proteins were detected with higher
frequency compared to PASD1-2 only protein. Similar to
CRC samples, the PASD1 positive polyps samples were

2 (33.3%)

2 (33.3%)

mostly from patients aged ≥60 years old (80%) but males
showed higher frequency (80%) (Supplementary S3). All
samples were from Chinese patients, 80% of the polyps
were at the distal colon and all were hyperplastic polyps.
3.4 Interferon-ɣ (IFN-ɣ) release assay towards CD4
PASD1 peptides
Immunogenicity of the CD4 PASD1 peptides was
carried out using an ELISpot assay. About 21.7% (13/60)
CRC samples and 23.5% (4/17) polyps patients showed
positive CD4 immune response with interferon-gamma
(IFN-ɣ) secretion toward any of the PASD1 peptides
(Table 4). Of these, 7 CRC samples (11.7%) showed IFN-ɣ
release towards PASD1(1) peptide, 1 sample (1.7%) with
PASD1(2) peptide and 5 samples (8.3%) with PASD1(3).
In polyps, 1 sample (5.9%) secreted IFN-ɣ towards PASD1
(1) and PASD1 (2) peptides, respectively, and 2 out of
17 samples (11.8%) secreted IFN-ɣ towards PASD1 (3)
peptide. PASD1(1) was the most immunogenic peptide in
CRC samples while PASD1(3) was the most immunogenic
peptide in polyps.
In the ELISpot assay, the results were considered
positive only if the number of spots counted in either
one of the PASD1 peptides was at least twice the number
of spots presented in the control cultures of cells only
(without any peptide) and the irrelevant CD4 peptide
(irCD4) (Ait-Tahar et al., 2011). The irCD4 peptide was
the peptide derived from HIV-1 reverse transcriptase
with sequence DESFRKYTAFTIPSMNNETP. It was
selected as the negative control peptide as it has a stable
reverse transcriptase structure of heterodimer made up
of 51-kDa and 66-kDa subunits and was less affected by
heterodimerization binding. Thus, it served as a good
negative control peptide for the PASD1 peptide in this
study.
3.5. Cytotoxicity assay
Based on availability and positive IFN-ɣ release, the T cells
from samples C5, C12, C32, C6 from CRC samples and
1 normal healthy volunteer T cell were expanded in vitro
and pulsed with their respective peptides based on the
outcome from their response in the ELISpot assay. These
T cells later were cocultured with SW480 and HCT116
CRC lines in a dose-dependent fashion as mentioned in
the method before. The cytotoxicity effect was quantitated
via apoptosis assay and analyzed using flow cytometry. The
representative data is shown with sample C5 (Figure 3). Post
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PASD1a antibody

PASD1b antibody

a)

b)

c)

d)

e)

f)

g)

h)

Figure 2. Representative IHC staining of the human tissues with PASD1a antibody (the left
column) and PASD1b antibody (right column). A) Normal testis tissue (positive control)
stained with PASD1a antibody. B) Normal testis tissue (positive control) stained with
PASD1b antibody. C) Normal tonsil tissue (negative control) stained with PASD1a antibody.
D) Normal tonsil tissue (negative control) stained with PASD1b antibody. E) CRC tissue
stained with PASD1a antibody. F) CRC tissue stained with PASD1b antibody. G) Polyps
tissue stained with PASD1a antibody. H) Polyps tissue stained with PASD1b antibody. Black
arrows refer to the brown staining in the nucleus and/or cytoplasm of the cells, suggesting
positive PASD1-1 and/or PASD1-2 protein expressions. No brown staining was observed
within the nucleus and/or cytoplasm of the tissues of C, D and H suggesting no expression
of these proteins. Photos were taken under 200× magnification.
Table 3. PASD1 protein expression in CRC samples.

Classifications

Criteria

Negative (-)

< 5% of tumor cells

CRC
PASD1-1
PASD1-2
expression (n, %) expression (n, %)
41 / 60 (68.3%)
58 / 60 (96.7%)

Weak positive (+)

6 to 25% of tumor cells

13 / 60 (21.7%)

Polyps
PASD1-1
PASD1-2
expression (n, %) expression (n, %)
12 / 17 (70.6%)
17 / 17 (100%)

2 / 60 (3.3%)

4 / 17 (23.5%)

0 / 17 (0.0%)

Moderate positive (++) 26 to 74% of tumor cells 6 / 60 (10.0%)

0 / 60 (0.0%)

1 / 17 (5.95%)

0 / 17 (0.0%)

Strong positive (+++)

0 / 60 (0.0%)

0 / 17 (0.0%)

0 / 17 (0.0%)
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Table 4. Positive CD4 immune response towards PASD1 peptides in CRC and polyps sample.
Quantification is through IFN-Ɣ release assay ELISpot. C = cancer sample, P = polyps sample.

Sample ID

Interferon – Ɣ release towards PASD1 peptides/50,000 cells (spots per well)
PASD1 (1)

PASD1 (2)

PASD1 (3)

Cells only

irCD4

PHA

C1

2±2

5±1

49 ± 10

4±4

4±1

216 ± 17

C5

9±4

4±2

3±2

4±4

2±1

127 ± 13

C6

2±1

6±4

2±1

2±1

2±1

136 ± 7

C9

7±3

2±1

2±1

2±1

2±1

412 ± 15

C12

185 ± 9

5±4

14 ± 8

13 ± 4

1±4

325 ± 21

C16

9±8

6±2

7±1

7±2

3±3

128 ± 14

C18

5±3

4±4

8±2

5±4

5±1

276 ± 11

C19

4±4

2±1

9±3

4±1

6±2

159 ± 10

C26

17 ± 6

2±2

7±5

6±6

3±1

120 ± 17

C27

9±6

5±3

7±3

3±2

2±2

180 ± 8

C28

10 ± 8

3±2

8±4

7±2

5±3

131 ± 6

C32

78 ± 15

7±3

26 ± 5

17 ± 7

4±2

153 ± 7

C47

4±4

3±2

8±3

3±1

3±2

110 ± 12

P6

6±2

4±1

10 ± 3

4±1

3±1

136 ± 9

P7

2±1

3±2

7±3

2±1

2±1

150 ± 20

P8

8±5

57 ± 10

6±2

4±1

7±3

275 ± 17

P12

89 ± 22

6±2

25 ± 6

16 ± 7

4±1

143 ± 10

18 h of coculture, 57.20% of PASD1-positive SW480 cells
showed late apoptosis and 2.95% of the cells were in early
apoptosis (Figure 3g). No significant lysis was observed
in the PASD1-negative HCT116 cell line (Figure 3e) and
irCD4-cultured T cell line (Figure 3f). These controls
showed a lower percentage of late and early apoptotic
cells between 1% and 3%. Of the four CRC samples that
were tested for cytotoxicity assay, only sample C5 showed
a significant cytotoxicity effect on PASD1-positive SW480
cell lines and the T cells were stimulated against PASD1 (1)
peptide. No significant cytotoxicity effects were observed
in samples C6, C12, C32 and normal healthy control (data
not shown). This study is the first to show data to suggest
CD4 Th cell killing in the PASD1 positive SW480 cell lines
via apoptosis.
3.6. Cytokine analysis
Cytokine was quantified from the coculture cells consisting
of CRC cell lines (SW480 and HCT116) and T cell lines
generated from samples C5, C12, C32, C6 and normal
healthy control. The cytokines measured were IL-17A,
IFN-ɣ, TNF, IL-10, IL-6 and IL-4. IL-17A and IL-6 levels
were the highest released during the co-culture while no
TNF, IL-10 and IL-4 were detected in all of the samples
(Figure 4). IL-17A was highest at 12.19 pg/ml in samples
C12 and C6 while IL6 was detected between 6.75 and 10.00
pg/mL in samples C5 and C32. Only two samples (C5 and

C12) released IFN-ɣ throughout the coculture (between
0.51 and 1.76 pg/mL).
3.7. Descriptive frequency correlation of patients’
demographic data with PASD1 expression and T cell
response
Descriptive frequency correlation of the demographic
data, PASD1 expression and immunogenicity of CRC and
polyps samples towards PASD1 peptides were analyzed.
Most of the patients were more than 60 years old,
female and of the Chinese ethnicity. Cancer originated
in the rectosigmoid part of the colon and patients were
diagnosed at an advanced stage of stage T3 or T4. Positive
PASD1-1 protein expression was also observed in all of
these patients. Of these, only samples C5 and C9 showed
positive PASD1 mRNA expression. In polyps samples, no
correlation in PASD1 mRNA or protein expression was
observed although all of the polyps samples elicited CD4
T cell response towards any of the PASD1 peptides.
4. Discussion
Out of the 60 CRC samples collected in this study from
April 2018 to October 2019, 36 were from male patients
and 24 from female patients. This sex proportion is
consistent with the Malaysia National Cancer Registry
Report (MNCRR 2012–2016), where a higher incidence of
male CRC patients was recorded compared to the female
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Figure 3. Immunophenotyping and apoptosis assay results for sample C5. a) The cocultured cells population based on
its size and granularity, b) Singlet cells, c) Gated singlet cells quantitated, d) Live PASD1-positive SW480 cells population
that was positively stained with calcein. Apoptotic cells quantitated in T cells cultured with e) PASD1-negative HCT116
cell line control, f) irCD4 peptide control, and g) SW480 PASD1-positive cell line. The blue color indicates the late
apoptotic cells while the red color showed the early apoptotic cells. Live and necrotic cells were represented with yellow
and purple colors respectively.

Figure 4. Cytokines level measured following 18 h of coculture. IL-17A and IL-6 were
detected in all of the CRC and normal control samples cultured with a PASD1-positive
SW480 cell line whereas only two samples (C5 and C12) released IFN-gamma. Some
cells e.g., T cells only, C5 HCT116, irCD4 C5 SW480 did not show any detectable
cytokine production, hence no bar chart for these respective samples. Error bar
indicates mean with SEM.

(Azizah et al., 2019). It could be due to the sex-hormonal
differences between males and females that affect CRC
incidence and progression. Lower sex hormone-binding
globulin (SHBG) and testosterone levels along with a
higher proportion of estradiol over testosterone were
correlated with a higher risk of developing CRC in males
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(Lin et al., 2013). As for the ethnicity, equivalent samples
were collected from Malay and Chinese while 3.3% were
from Indian and other ethnicities such as Punjabi and
Kenyah. Hence, this was a reasonable representation
of the Malaysian population as there was multiethnic
participation in the study.

SUKOR et al. / Turk J Biol
The median age in our sample population was 66.5
years old. About 68.3% of the total samples were patients
with age more than 60 years old during diagnosis. This is
in concordance with what was reported in MNCRR 2012–
2016. The age-standardized rate (ASR) of patients aged 60
to 64 years old was 70 cases per 100,000 and the increasing
pattern was shown in patients more than 75 years old
(Azizah et al., 2019). One possible reason that contributes
to this is the aging process that eventually reduced the
lymphocytes’ production hence weakening the immune
system function or known as immunosenescence (Giunco
et al., 2019). Thus, precancerous and tumor cells were less
recognized by the minimally produced immune cells. This
evasion of immunosurveillance is also listed as one of the
emerging hallmarks of cancer (Hanahan and Weinberg,
2011).
In terms of cancer staging, poor awareness regarding
CRC early symptoms and risk factors might be the reason
why most of our sample population were diagnosed at a
late stage of T3 and T4. In a study that was conducted in
the Klang Valley area, there were around 8.2% and 8.5%
of respondents without any knowledge of early signs and
risk factors of CRC, respectively, indicating there is still
limited awareness among urban Malaysians about this
disease (Sindhu et al., 2019). However, a recent study
suggested that a factual-based mass media campaign on
CRC can enhance awareness in over 65% of the Malaysian
participants (Schliemann et al., 2020).
The majority (83.3%) of the tumors among CRC
patients in this study were located in the distal (left-sided)
part of the colon. However, there was no clear evidence on
the relation between the location of the tumor and cancer
prognosis due to contradictory findings in several studies
(Bustamante-Lopez et al., 2019).
Almost all of the histological subtype of CRC in
this study was from adenocarcinoma which consisted
of classical and mucinous adenocarcinoma. This might
be due to the nature of the CRC itself which originates
from epithelial cells of the colorectal mucosa (Fleming
et al., 2012). Only one of our samples showed properties
of the rare neuroendocrine carcinoma (NEC) subtype
and this patient was diagnosed with stage IV CRC. The
polyps patients were males (70.5%). Our results supported
the recent study conducted at Serdang Hospital which
reported that the polyps detection rate is higher in males
(22.5%) than in females (17.1%) (Tan et al., 2019). The
protective function provided by the estrogen released
causing reduced angiogenesis was postulated to have a
crucial role in lowering the risk of colonic polyps formation
among women (Yang et al., 2013). This might be one of the
possible reasons why polyps detection rates were found
higher in males compared to females. The polyps samples
in this study were mostly hyperplastic polyps (70.5%). The
hyperplastic polyp is a type of rarely malignant polyps

whereas most sessile polyps are known as precancerous
colonic lesions with indefinite shapes (Pai et al., 2019). The
prevalence of colorectal polyp increased with age and a
similar trend was also observed in the Chinese (Pan et al.,
2020) and Thai populations (Siripongpreeda et al., 2016).
This might be the result of both immune senescence and
genetic instability resulting in cellular destruction (Vijg J
et al., 2017). The healthy cells can continue to divide out
of control and thus develop into colorectal polyps among
the elderly group.
We observed a strong positive PASD1 mRNA
expression in the SW480 CRC cell line and it was the only
CRC cell line expressed with PASD1 mRNA. This finding is
following previous reports (Liggins et al., 2004). SW480 is
a Dukes’ B colorectal adenocarcinoma cell line. The reason
for this remains elusive, however, SW480 also expresses
other X-linked CTAs such as MAGEA2, MAGEA3,
MAGEA6 and GAGE8 (Yamada et al., 2013). Thus, the
SW480 cell line serves as a good positive control cell
line model in several CTAs expression studies including
PASD1.
The alternatively spliced variant PASD1_v2 showed
the highest expression in CRC groups and 69.5% of CRC
patients expressing PASD1_v2 were diagnosed at the late
stage of T3 and T4, which often leads to a poor prognosis
of the disease. This could suggest the potential role of
PASD1_v2 in colorectal carcinogenesis and might serve as
a favorable predictive marker of high-risk CRC patients.
This supports a previous study on diffuse large B cell
lymphoma (DLBCL) cell lines that showed the potential
of PASD1_v2 as a subtyping marker in recognizing
high-risk DLBCL patients as it was expressed only in
poor prognosis nongerminal center subtype derived cell
lines (Liggins et al., 2004). Interestingly, PASD1 mRNA
expression was observed in many of the hyperplastic
polyps samples instead of tubulovillous or tubular
adenoma type. Hyperplastic polyps were reported to have
lesser potential in neoplastic transformation compared to
the other types of polyps due to the limited expression of
cancer-related genes (Rahmatallah et al., 2017). To the best
of our knowledge, the expression of PASD1 has not yet
been reported in any types of colorectal polyps samples.
Nevertheless, studies on the differentially expressed genes
among unifocal colon polyp samples show that there were
approximately 274 upregulated genes in colon polyps
and they play a crucial role in immune response (Lian et
al., 2015). Therefore, the expression of PASD1 in polyps
samples could be further explored especially in terms of its
biological function in the patients’ immune systems.
The IHC staining results on the human normal testis
tissue (positive control for PASD1 expression) suggested
that the common regions of PASD1-1 and PASD1-2
were expressed at the nuclei and cytoplasm while the
unique PASD1-2 protein region was restricted only at
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the nucleus part of the primary spermatogonia cells
near basal membrane in testicular tubules. The unique
region of PASD1-2 might have some deficiency in the
translational process that affects the transportation of the
protein into the cytoplasm that needs further exploration.
The testis organ is one of the immune privilege sites due
to a lack of MHC class I expression (Scanlan et al., 2004).
Therefore, targeting CTAs such as PASD1 may not lead to
a catastrophically autoimmune response against patients’
own normal and germline tissues. This is imperative in
minimizing the adverse effects of immunotherapy on
normal healthy tissues in CRC patients. As expected with
normal tissues, no PASD1 expression was observed in the
human normal tonsil tissue (negative control for PASD1
expression, indicating the high specificity of the PASD1
antibodies in detecting the PASD1 protein expression.
This study is also following previously published data on
PASD1 protein expression and localization in the tissues
(Cooper et al., 2006; Johdi et al., 2019). These findings
show that PASD1 is indeed an ideal candidate for an
immunotherapeutic target due to its expression specificity.
This current study shows the highest PASD1 protein
expression in the CRC population (31.7%). A previous study
described only 17.4% PASD1 expression in CRC (Soh et al.,
2019). The possible reason for these discrepancies was the
PASD1 antibodies used in both studies. In our study, the
PASD1 antibodies were in-house monoclonal antibodies
designed by the collaborators to specifically target the
common and unique regions of PASD1 proteins (Cooper
et al., 2006). PASD1a recognized 195 to 474 aa (a common
region in both PASD1-1 and PASD1-2 proteins) and
PASD1b recognized 540 to 773 aa, the unique region that
only presented in the longer PASD1-2 protein. A previous
study reported using a commercially available polyclonal
PASD1 antibody targeting 301 to 600 aa (Thermo Fisher
Scientific) (Soh et al., 2019). The differences in binding
epitopes for PASD1 antibodies may result in disparities
in PASD1 protein expression levels in CRC samples.
Secondly, a bigger sample size increases the chances of
detection for positive PASD1. Our study analyzed 60 CRC
patients compared to only 23 CRC patients in the previous
study [32]. Moreover, the staining reagents and materials
also play a crucial role in protein detection. The kit used
in our study, EnVision FLEX Mini kit, high pH, Dako
autostainer/autostainer plus (Dako, Denmark) is a wellestablished kit that is optimized for IHC detection and
commonly used in clinical and published papers.
We demonstrated a higher expression of PASD1-1
and PASD1-2 common region compared to the unique
PASD1-2 protein. Similar findings were also observed in
the PASD1 expression study in lymphoma particularly
the DLBCL patients (Cooper et al., 2006; Johdi et al.,
2019). This might due to the longer epitope coverage
in the PASD1-1 and PASD1-2 common region which
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started from 195 to 474 aa while the unique region only
covered from 540 to 773 aa (Cooper et al., 2006). Hence,
a larger binding epitope was presented at the common
region which eventually may increase the frequency and
chances of antibody binding at that particular site. We also
observed a low to moderate brown staining expression at
the common region of PASD1-1 and PASD1-2 mainly at
the lamina propria and muscularis mucosa of the late-stage
CRC tissue. This could be due to the presence of invading
cancer cells in several nodules and other neighboring
organs. Besides CRC and polyps, PASD1 expressions have
been reported in other cancers such as DLBCL and acute
myeloid leukemia (AML) (Cooper et al., 2006) and glioma
patients (Li et al., 2019) in which, all the studies involved
cancer at an advanced stage. This shows that PASD1 might
have a role in carcinogenesis and a potential subtyping
marker in recognizing high-risk cancer.
Having said that, a low to moderate expression level of
the common region PASD1-1 and PASD1-2 protein was
also detected in polyps while no PASD1-2 protein from a
unique region was detected although PASD1_v2 mRNA
was expressed in some of the polyps samples. This can
occur due to point mutation that may lead to a reduced
protein expression in this region as shown in a study
with MAGE-A4 where certain point mutations affect the
protein expression and thermal stability of the protein
(Hagiwara et al., 2016). Also, the absence of PASD1-2
protein expression in polyps that were detected in many
cancers might be well correlated with the stage of the
disease.
In general, we observed a higher PASD1 mRNA
expression level compared to the protein level. The
discrepancy in RNA and protein expression has been
reported in several CTAs expression studies including
in FATE-1 (Doghman-Bouguerra et al., 2020). This is
due to epigenetic and nonepigenetic events. Epigenetic
modifications such as DNA methylation could affect the
CTAs expression and regulation mechanism in normal and
cancer cells and induce promoter silencing mainly in the
early stage of CRC, hence reducing the gene expression.
This could explain why the PASD1 protein staining was
mostly observed in stages 3 and 4 CRC patients. Other
factors could be the posttranslational histone modification
that may lead to the downregulation of PASD1 expression
in CRC and polyps patients. Histone deacetylation process
can lead to chromatin compaction thus inhibiting the
binding of the transcription factors and RNA polymerase
at the promoter region, and therefore results in limited
gene expression.
Nonepigenetic events such as cytokine levels may also
contribute to CTAs’ expression levels. As an example,
Semenogelin 1 (SEMG1) expression is positively correlated
with the presence of interleukins (IL-4 and IL-6) in
multiple myeloma cells (Zhang et al., 2009). Interestingly,
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PASD1 upregulation was associated with the activation of
signal transducer and activator of transcription 3 (STAT3).
The STAT3 transcription factor is predominantly activated
by the presence of the IL-6 cytokine. However, in our
study, a low level of IL-6 and the absence of IL-4 cytokines
were detected in the CRC samples. This might explain the
low or no PASD1 expression detected in some of the CRC
patients.
Also, the PASD1 protein expression could be below
the detection level of the IHC technique compared to the
highly sensitive method in qRT-PCR. The IHC technique
highly depends on the antigen-antibody epitope binding.
The translation process from mRNA to protein involved
many factors (stability of the mRNA template, binding
of each amino acid to the most suitable transfer RNA
(tRNA), the specificity of the codon base pairing) as well
as processes (initiation, elongation, termination) and it is
not a straightforward process. Thus, disparities in mRNA
and protein expressions were expected. Both techniques
complement each other and are crucial in determining
the overall landscape of PASD1 expression. However,
the IHC technique is the most appropriate method to
determine the PASD1 cellular localization in the tissue and
possible secondary PASD1 isoform which is not within the
detection range of currently available common or unique
PASD1 epitopes (Ait-Tahar et al., 2011). Therefore, this
may provide a better in-depth study avenue to improve the
epitope target for PASD1 antibodies in the future.
The current study was also performed to identify short
immunogenic PASD1 peptides capable of eliciting CD4
Th cell responses. Such peptides could then be included
in a CRC vaccine immunotherapy as well as colorectal
polyps expressing PASD1. Three potential CD4 Th
PASD1 peptides of 8 amino acids in length were studied
and all of them were able to elicit interferon-ɣ responses
in some CRC and polyps patients, with the PASD1 (1)
and PASD1 (3) peptides being identified as the most
immunogenic peptides in CRC and polyps, respectively.
PASD1 (1) peptide binds to an epitope at the common
region of the PAS domain (38 to 47 aa) and is frequently
found in most solid tumors (Cooper et al., 2006). This is
possibly the reason for the higher detection frequency of
PASD1 (1) peptides compared to the other peptides and
has the potential to be further explored as a candidate for
immunotherapy. The lack of significant homology of the
PASD1 peptides with other molecules combined with the
absence of any significant response with the irrelevant
peptide and normal sample demonstrates the specificity of
the response to PASD1.
The interferon-ɣ responses to the PASD1 peptides were
present in 11 of the 60 CRC patients and 3 of the 17 polyps
patients whose tumors expressed PASD1 protein. However,
2 CRC patients and 1 polyps patient recognized the PASD1
peptides but lacked detectable PASD1 protein. A disparity

between PASD1 expression and immunogenicity has
been described previously (Ait-Tahar et al., 2011) and it
is possible that the immunolabeling techniques used here
may not constitute a sufficiently sensitive tool to identify
low levels of PASD1 protein expression. Importantly, high
levels of target protein expression may not be necessary
for immune recognition. To date, this is the first study
describing the CD4 T cell response towards PASD1
peptides in CRC and colorectal polyps patients. Previous
studies have reported on CD4 responses in DLBCL
patients (Ait-Tahar et al., 2011).
Interestingly, all of the polyps samples that showed
CD4 T cell response against PASD1 peptides were from
hyperplastic polyps, a type of polyps with less association
with cancer development (Rahmatallah et al., 2017). This
is consistent with the PASD1 protein expression data. This
could suggest that hyperplastic polyps do have malignant
potential due to hypermethylation which affects their
morphological features to transform into malignant cells
and could be further elucidated.
We managed to raise CD4 Th cell lines from 4 CRC
patients and 1 normal healthy volunteer. T cells from
samples C5, C12 and C32 showed the highest response
toward PASD1 (1) peptide while sample C6 exhibited
the highest response towards PASD1 (2) peptide. The
normal healthy sample was raised in PASD1 (1). Of these,
only the C5 sample showed significant lysis of PASD1positive SW480 tumor cell lines but not in the PASD1negative HCT116 cell line, normal healthy sample and
irCD4. This suggests that the CD4 T cells were able to
recognize endogenously expressed PASD1 and specifically
lyse PASD1-positive cell lines. The result is in agreement
with data from a previous study on CD4 T cell response
to PASD1 protein in DLBCL patients where a higher
percentage of cell lysis was observed in the PASD1positive Thiel cell line compared to the PASD1-negative
OCI-Ly3 and SUDHL-6 cell line control (Ait-Tahar et al.,
2011). However, further optimization may be required to
obtain a good baseline in normal samples. We also did not
observe significant apoptosis in the other 3 CRC samples
although the samples produced high CD4 T cell response
after stimulation with the PASD1 peptide in ELISpot.
Although CD8 cytotoxic T lymphocytes (CTLs) are the
main cells involved in tumor cell killing, previous studies
have reported the imperative roles of the CD4 T cells in
orchestrating antitumor response (Ait-Tahar et al., 2011).
The CD4+ T cells act as central coordinators by either
suppressing or promoting the antitumor CTL response
via effector cytokine secretion such as interferon-gamma
and interleukin 17A. This provides evidence of measuring
the CD4 immune response in understanding their role in
antitumor response in CRC and polyps.
Interleukin 17A (IL-17A), interferon-gamma (IFN-Ɣ)
and interleukin 6 (IL-6) were significantly secreted by
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CD4 Th cell lines from 4 CRC patients when cocultured
with PASD1-positive SW480 CRC cell lines. IL-17A
is a proinflammatory cytokine, known for its function
in regulating tumor progression in CRC (Zhao et al.,
2020). It also plays a crucial role in tumor progression by
increasing the tumor size. On the other hand, IL-6 is highly
associated with the production of CD4 T cells (Sofi et al.,
2009). Thus, IL-17A and IL-6 cytokines have an inverse
correlation in tumor immunology. The coculture of CD4
Th cell lines from C5 with SW480 cell line showed a lower
level of IL-17A because the SW480 cancer cells underwent
apoptosis while high IL-6 was detected due to the high
proliferation of CD4 Th cell lines from C5 which cause the
cell cytotoxicity. This provides evidence of the mechanism
of homeostasis between T cells and tumor cells.
5. Conclusion
This current study shows the highest PASD1 protein
expression in the CRC population. This is the first report
on CD4 Th response to a PASD1 by CRC and polyps
patients and cell cytotoxicity to PASD1-positive cell CRC
cell line. These CD4 Th peptides hold a future potential for
use in conjunction with PASD1 peptides eliciting CTL in
a vaccine for CRC and polyps patients’ immunotherapy.
Some limitations of the study included samples size and
insufficiency of matched FFPE tissue sections and blood
samples due to priority having to be given to the diagnostic
pathology.
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Supplementary S1: Demographic data of CRC patients. NA = Non-applicable, SD= standard deviation,
IQR=Inter quartile range.
Demographic data
Age

≤ 60 years old
> 60 years old
Sex
Male
Female
Ethnicity
Malay
Chinese
Indian
Others
Surgical resection
Yes
No
Tumor/polyps
location
Distal
Proximal
Types of the
tumor /polyps

Histological grade

Tumor stage
(TNM)
T1
T2
T3
T4
Nodal metastasis
N0
N1-2
Distant metastasis
M0
M1

CRC (n = 60)
(n, %)
Mean = 65 (30-85 yo)
Median = 66.5;
SD = 11.6; IQR = 13.5

Polyps (n = 17)
(n, %)
Mean = 67 (51–85 yo)
Median = 68 ;
SD = 9.2 ; IQR = 12

Normal (n = 13)
(n, %)
Mean = 64 (50 – 76 yo)
Median = 64 ;
SD = 7.5 ; IQR = 8

19 (31.7%)
41 (68.3%)

2 (11.8%)
15 (88.2%)

4 (30.8%)
9 (69.2%)

36 (60.0%)
24 (40.0%)

12 (70.5%)
5 (29.4%)

9 (69.2%)
4 (30.8%)

28 (46.7%)
28 (46.7%)
2 (3.3%)
2 (3.3%)

7 (41.2%)
10 (58.8%)
0
0

5 (38.5%)
7 (53.8%)
1 (7.7%)
0

60 (100.0%)
0 (0.0%)

NA

NA

50 (83.3%)
10 (16.7%)
Adenocarcinoma
59 (98.3%)
Neuroendocrine
carcinoma
1 (1.7%)

11 (64.7%)
6 (35.3%)
Hyperplastic polyps
12 (70.5%)
Tubulovillous adenoma
4 (23.5%)
Tubular adenoma
1 (6.0%)
(only applicable for
adenomatous polyps)
High-grade dysplasia
1 (20.0%)
Low-grade dysplasia
4 (80.0%)

NA

10 (16.7%)
13 (21.6%)
25 (41.7%)
12 (20.0%)

NA

NA

23 (38.3%)
37 (61.7%)

NA

NA

48 (80.0%)
12 (20.0%)

NA

NA

Well-differentiated
33 (55.0%)
Moderately
Differentiated
26 (43.3%)
Poorly differentiated
1 (1.7%)

NA

NA

1
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Supplementary S2: Summary of PASD1 protein expression and clinical characteristics of CRC patients
Characteristics

2

Positive PASD1 protein expression in CRC patients
PASD1-1 and PASD1-2
PASD1-2 only
(n = 19)
(n = 2)

Age
≤ 60 years old
> 60 years old

7/19 (36.8%)
12/19 (63.2%)

1/2 (50.0%)
1/2 (50.0%)

Sex
Male
Female

7/19 (36.8%)
12/19 (63.2%)

1/2 (50.0%)
1/2 (50.0%)

Race
Malay
Chinese
Indian
Others

7/19 (36.8%)
11/19 (57.9%)
0/19 (0.0%)
1/19 (5.3%)

1/2 (50.0%)
1/2 (50.0%)
0/2 (0.0%)
0/2 (0.0%)

Tumor location
Distal
Proximal

16/19 (84.2%)
3/19 (15.8%)

0/2 (0.0%)
2/2 (100.0%)

Surgical resection
Yes
No

19/19 (100.0%)
0/19 (0.0%)

2/2 (100.0%)
0/2 (0.0%)

Tumor stage (TNM)
T1
T2
T3
T4

2/19 (10.5%)
5/19 (26.3%)
7/19 (36.8%)
5/19 (26.3%)

0/2 (0.0%)
1/2 (50.0%)
1/2 (50.0%)
0/2 (0.0%)

Nodal metastasis
N0
N1-2

12/19 (63.2%)
7/19 (36.8%)

1/2 (50.0%)
1/2 (50.0%)

Distant metastasis
M0
M1

14/19 (73.7%)
5/19 (26.3%)

2/2 (100.0%)
0/2 (0.0%)

Types of tumor
Adenocarcinoma
Neuroendocrine carcinoma

19/19 (100.0%)
0/19 (0.0%)

2/2 (100.0%)
0/2 (0.0%)

Histological grade
Well-differentiated
Moderately differentiated
Poorly differentiated

13/19 (68.4%)
5/19 (26.3%)
1/19 (5.3%)

2/2 (100.0%)
0/2 (0.0%)
0/2 (0.0%)
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Supplementary S3: Summary of PASD1 protein expressions with clinical data of polyp patients
Characteristics

Age
≤ 60 years old
> 60 years old

Positive PASD1 protein expression in polyp
patients
PASD1-1 and PASD1-2
PASD1-2 only
(n = 5)
(n = 0)
1/5 (20.0%)
4/5 (80.0%)

0/0 (0.0%)
0/0 (0.0%)

Sex
Male
Female

4/5 (80.0%)
1/5 (20.0%)

0/0 (0.0%)
0/0 (0.0%)

Ethnicity
Malay
Chinese

0/5 (0.0%)
5/5 (100.0%)

0/0 (0.0%)
0/0 (0.0%)

Polyp location
Distal
Proximal

4/5 (80.0%)
1/5 (20.0%)

0/0 (0.0%)
0/0 (0.0%)

Types of polyp
Hyperplastic polyp
Tubulovillous adenoma
Tubular adenoma

5/5 (100.0%)
0/5 (0.0%)
0/5 (0.0%)

0/0 (0.0%)
0/0 (0.0%)
0/0 (0.0%)

0/5 (0.0%)
0/5 (0.0%)

0/0 (0.0%)
0/0 (0.0%)

Histological grade
(only applicable for adenomatous polyps)
High-grade dysplasia
Low-grade dysplasia

3

